Making clinical decisions based on measurable residual disease improves the outcome in Multiple Myeloma
The assessment of bone marrow measurable residual disease (MRD) has consistently shown a significant prognostic value in patients with multiple myeloma (MM), with a benefit in survival outcomes associated with MRD negativity surpassing the value of complete response. Using MRD to guide treatment in MM is potentially as useful as Serum Protein Electrophoresis and light chain measurement, especially in patients in stringent Complete Response.